Search Results - Hong‐Hong Yan

Refine Results
  1. 1
    Multiple primary malignancies involving lung cancer

    Multiple primary malignancies involving lung cancer by Feng Li, Wen‐Zhao Zhong, Feiyu Niu, Ning Zhao, Jin‐Ji Yang, Hong‐Hong Yan, Yi‐Long Wu

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    <i>EGFR</i> mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

    <i>EGFR</i> mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China by Can Pi, Chong‐Rui Xu, Mingfeng Zhang, Xiaoxiao Peng, Xue‐Wu Wei, Xing Gao, Hong‐Hong Yan, Qing Zhou

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

    Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations by Yang-Si Li, Ben‐Yuan Jiang, Jin‐Ji Yang, Hai‐Yan Tu, Qing Zhou, Wei‐Bang Guo, Hong‐Hong Yan, Yi‐Long Wu

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

    Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803) by Yi‐Long Wu, Caicun Zhou, Ying Cheng, Shun Lü, G.-Y. Chen, Cheng Huang, Yulu Huang, Hong‐Hong Yan, Shengxiang Ren, Yao-Bin Liu, Jin‐Ji Yang

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer

    Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer by Zhong‐Yi Dong, Hao-Ran Zhai, Qingyi Hou, Jian Su, Si‐Yang Liu, Hong‐Hong Yan, Yang-Si Li, Zhiyong Chen, Wen‐Zhao Zhong, Yi‐Long Wu

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

    Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial by Qing Zhou, Jin‐Ji Yang, Zhihong Chen, Xu‐Chao Zhang, Hong‐Hong Yan, Chong‐Rui Xu, Jian Su, Hua‐Jun Chen, Hai‐Yan Tu, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

    A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R by E‐E Ke, Qing Zhou, Qiuyi Zhang, Jian Su, Zhihong Chen, Xu‐Chao Zhang, Chong‐Rui Xu, Jin‐Ji Yang, Hai‐Yan Tu, Hong‐Hong Yan, Yichen Zhang, Feiyu Niu, Yi‐Long Wu

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients

    Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients by Jian Su, Wen‐Zhao Zhong, Xu‐Chao Zhang, Ying Huang, Hong‐Hong Yan, Jin‐Ji Yang, Zhong‐Yi Dong, Zhi Xie, Qing Zhou, Xiao-sui Huang, Danxia Lu, Wenqing Yan, Yi‐Long Wu

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

    Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status by Wen‐Zhao Zhong, Xue‐Ning Yang, Hong‐Hong Yan, Xu‐Chao Zhang, Jian Su, Zhihong Chen, Ri-Qiang Liao, Qiang Nie, Song Dong, Qing Zhou, Jin‐Ji Yang, Hai‐Yan Tu, Yi‐Long Wu

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

    Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study by Xue Bai, Dehua Wu, Si-Cong Ma, Jian Wang, Xin-Ran Tang, Shuai Kang, Qiang Fu, Chuanhui Cao, He-San Luo, Yuhan Chen, Hongbo Zhu, Hong‐Hong Yan, Yi‐Long Wu, Zhong‐Yi Dong

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

    Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer by Jia‐Yi Deng, Qing Gou, Lingling Yang, Zhihong Chen, Mingyi Yang, Xiaorong Yang, Hong‐Hong Yan, Xue‐Wu Wei, Jiaqi Liu, Jian Su, Wen‐Zhao Zhong, Chong‐Rui Xu, Yi‐Long Wu, Qing Zhou

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status

    Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status by She-Juan An, Zhi Hong Chen, Jian Su, Xu‐Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony Mok, Yi‐Long Wu

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    <i>EGFR</i> Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

    <i>EGFR</i> Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas by Zhiyong Chen, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Xue-Ning Yang, Zhi Hong Chen, Jin-Ji Yang, Qing Zhou, Hong-Hong Yan, She-Juan An, Hua-Jun Chen, Ben‐Yuan Jiang, Tony Mok, Yi‐Long Wu

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

    Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma by Hao Sun, Si‐Yang Maggie Liu, Jiaying Zhou, Jintian Xu, Huang-Kai Zhang, Hong‐Hong Yan, Jiaojiao Huan, Pingping Dai, Chong‐Rui Xu, Jian Su, Yanfang Guan, Xin Yi, Rongshan Yu, Wen‐Zhao Zhong, Yi‐Long Wu

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

    A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations by Jin‐Ji Yang, Qing Zhou, Hong‐Hong Yan, X C Zhang, H J Chen, Hai‐Yan Tu, Z Wang, Chong‐Rui Xu, Jian Su, Banglu Wang, Bo Jiang, Xiaoyan Bai, Wen‐Zhao Zhong, Xue‐Ning Yang, Yi‐Long Wu

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

    Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized tri... by Qing Zhou, Ying Cheng, Jin‐Ji Yang, Mingfang Zhao, L. Zhang, X.-C. Zhang, Zhendong Chen, Hong‐Hong Yan, Yong Song, Juxiang Chen, Weineng Feng, Chong‐Rui Xu, Z. Wang, H.-J. Chen, Wen‐Zhao Zhong, Y.-P. Liu, Yi‐Long Wu

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival

    A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival by Chanyuan Zhang, Hao Sun, Junwei Su, Yuqing Chen, Shiling Zhang, Ming-Ying Zheng, Yufa Li, Jie Huang, Chao Zhang, Zaixian Tai, Miao Cai, Xuchao Zhang, Jian Su, Chong‐Rui Xu, Hong‐Hong Yan, Hua‐Jun Chen, Yi‐Long Wu, Jin‐Ji Yang

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

    MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors by Lun-Xi Peng, Guang‐Ling Jie, Anna Li, Si‐Yang Maggie Liu, Hao Sun, Mei-Mei Zheng, Jiaying Zhou, Jia‐Tao Zhang, Xu‐Chao Zhang, Qing Zhou, Wen‐Zhao Zhong, Jin‐Ji Yang, Hai‐Yan Tu, Jian Su, Hong‐Hong Yan, Yi‐Long Wu

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

    Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer by Jin‐Ji Yang, Hua‐Jun Chen, Hong‐Hong Yan, Xu‐Chao Zhang, Qing Zhou, Jian Su, Zhen Wang, Chong‐Rui Xu, Yi-Sheng Huang, Bin-Chao Wang, Xue‐Ning Yang, Wen‐Zhao Zhong, Qiang Nie, Ri-Qiang Liao, Ben‐Yuan Jiang, Song Dong, Yi‐Long Wu

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

    Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I... by Yichen Zhang, Zhihong Chen, Xu‐Chao Zhang, Chong‐Rui Xu, Hong‐Hong Yan, Zhi Xie, Shaokun Chuai, Junyi Ye, Han Han‐Zhang, Zhou Zhang, Xiaoyan Bai, Jian Su, Bin Gan, Jin‐Ji Yang, Wenfeng Li, Wei Tang, Feng Luo, Xiao Xu, Yi‐Long Wu, Qing Zhou

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: